De Giorgi, Ugo Federico Francesco
 Distribuzione geografica
Continente #
NA - Nord America 189
EU - Europa 152
AS - Asia 99
AF - Africa 7
SA - Sud America 1
Totale 448
Nazione #
US - Stati Uniti d'America 184
CN - Cina 58
IT - Italia 53
IE - Irlanda 28
FR - Francia 14
SE - Svezia 14
BE - Belgio 11
GB - Regno Unito 8
IN - India 7
NL - Olanda 7
SG - Singapore 7
NG - Nigeria 5
CA - Canada 4
DE - Germania 4
IR - Iran 4
JP - Giappone 4
VN - Vietnam 4
PH - Filippine 3
PL - Polonia 3
TR - Turchia 3
ES - Italia 2
FI - Finlandia 2
IL - Israele 2
KR - Corea 2
UG - Uganda 2
AM - Armenia 1
BR - Brasile 1
HK - Hong Kong 1
HU - Ungheria 1
ID - Indonesia 1
MK - Macedonia 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
RO - Romania 1
RU - Federazione Russa 1
TW - Taiwan 1
UA - Ucraina 1
Totale 448
Città #
Chandler 40
Dublin 28
Fairfield 12
Nyköping 11
Torino 9
Houston 7
Medford 7
Redwood City 7
Shanghai 7
Seattle 6
Singapore 6
Turin 6
Ashburn 5
Beijing 5
Paris 5
Princeton 5
Abuja 4
Chengdu 4
Esneux 4
Genoa 4
Milan 4
New York 4
Pune 4
Calgary 3
Hangzhou 3
Jiaxing 3
Nanjing 3
Sigean 3
Wilmington 3
Bagnoli del Trigno 2
Bellingham 2
Brussels 2
Cambridge 2
Düsseldorf 2
Harvard 2
Hebei 2
Hoevenen 2
Istanbul 2
Jerusalem 2
Klaaswaal 2
Madrid 2
Parma 2
Rome 2
San Diego 2
Strijen 2
Vlaardingen 2
Woodbridge 2
Akron 1
Americana 1
Amsterdam 1
Ankara 1
Ann Arbor 1
Arau 1
Ashiharacho 1
Bacoli 1
Bacoor 1
Bangalore 1
Boston 1
Chandigarh 1
Changsha 1
Cluj-napoca 1
Deposit 1
Duncan 1
El Fuerte 1
Fremont 1
Frosinone 1
Gainesville 1
Guiyang 1
Harbin 1
Hayward 1
Hefei 1
Helsinki 1
Homer 1
Homps 1
Honolulu 1
Hyderabad 1
Isfahan 1
Jacksonville 1
Kagoshima 1
Kelseyville 1
Lagos 1
Lappeenranta 1
London 1
Los Angeles 1
Lyon 1
Macerata 1
Moncalieri 1
Nanchang 1
Nonette 1
Norwalk 1
Oslo 1
Padova 1
Pittsburgh 1
Plainville 1
Prilep 1
Riverton 1
Royal Leamington Spa 1
San Jose 1
Seoul 1
Seregno 1
Totale 301
Nome #
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 242
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21) 54
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 52
Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study 33
The prognostic value of pain in castration-sensitive prostate cancer 25
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society 17
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study 14
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort 11
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 9
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial 5
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line 1
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study 1
Totale 464
Categoria #
all - tutte 2.019
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.019


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 0 0 0 0 2 0 0 1 1 0 1 4
2020/202174 1 3 5 4 5 9 3 2 6 20 9 7
2021/2022100 4 11 2 11 6 5 3 5 14 3 18 18
2022/2023150 8 7 2 9 17 32 11 23 12 5 12 12
2023/2024131 20 16 6 13 7 18 3 16 8 15 6 3
Totale 464